Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

28.17USD
20 Sep 2018
Change (% chg)

$-0.46 (-1.61%)
Prev Close
$28.63
Open
$28.87
Day's High
$28.90
Day's Low
$27.75
Volume
355,671
Avg. Vol
401,147
52-wk High
$56.66
52-wk Low
$24.63

Select another date:

Thu, May 24 2018

BRIEF-Portola Pharmaceuticals Receives $100 Mln Milestone Payment From Healthcare Royalty Partners For FDA Approval Of Andexxa

* PORTOLA PHARMACEUTICALS RECEIVES $100 MILLION MILESTONE PAYMENT FROM HEALTHCARE ROYALTY PARTNERS FOR FDA APPROVAL OF ANDEXXA® Source text for Eikon: Further company coverage:

BRIEF-Portola Pharmaceuticals Q1 Loss Per Share $1.28

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

BRIEF-Portola Pharmaceuticals Plans To Appeal Negative CHMP Opinion For Betrixaban In The European Union

* PORTOLA PHARMACEUTICALS RECEIVES AND PLANS TO APPEAL NEGATIVE CHMP OPINION REGARDING MARKETING AUTHORIZATION FOR BETRIXABAN IN THE EUROPEAN UNION

EMA panel recommends against Portola's clot prevention drug

March 23 A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

BRIEF-EMA Panel Recommends Against Approval Of Portola Drug For Preventing Blood Clots Betrixiban

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL OF PORTOLA PHARMACEUTICALS' DRUG FOR PREVENTING BLOOD CLOTS BETRIXIBAN Source text (http://bit.ly/2pBz519) Further company coverage:

Select another date: